---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-293409"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2022-11-28T23:59:59+00:00"
generated_at: "2026-06-21T12:35:16.194639+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics receives Nasdaq extension to May 22, 2023 to regain minimum bid price compliance

## Summary
- Received second letter from Nasdaq granting 180-day extension to May 22, 2023 to regain minimum bid price compliance.
- Previously notified on May 24, 2022 of bid price below $1.00; original compliance period ended Nov 21, 2022.
- Company will evaluate options including a reverse stock split, if approved by stockholders.
- Failure to regain compliance by May 22, 2023 may result in delisting; rights to appeal exist.

## SEC filing metadata
- accession: 0001193125-22-293409
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2022-11-28T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312522293409/0001193125-22-293409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312522293409/d404851d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-293409
- JSON: https://secwatch.observer/filing/0001193125-22-293409.json
- Plain text: https://secwatch.observer/filing/0001193125-22-293409.txt

## Key facts
- Listing & Compliance Notices
  PLUS THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: November 22, 2022, the Company received a second letter from Nasdaq advising that the Company had been granted an additional 180 calendar days, or to May 22, 2023, to regain compliance with the Minimum Bid Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. Specifically, the Company has confirmed to Nasdaq that, if necessary, it will implement a reverse stock split of its outstanding common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312522293409/0001193125-22-293409-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.